• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.

    2/5/26 2:48:42 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    ENANTA PHARMACEUTICALS INC

    (Name of Issuer)


    Common Stock, par value $0.01 per share (the "Shares")

    (Title of Class of Securities)


    29251M106

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Capital Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    531,119.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    531,119.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    531,119.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Capital Institutional Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    595,851.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    595,851.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    595,851.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Capital Institutional Partners II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    150,355.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    150,355.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    150,355.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Capital Institutional Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    84,528.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    84,528.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    84,528.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Four Crossings Institutional Partners V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    108,002.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    108,002.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    108,002.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Capital Offshore Investors II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,110,733.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,110,733.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,110,733.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Capital (AM) Investors, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    60,191.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    60,191.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    60,191.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Capital F5 Master I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    176,083.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    176,083.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    176,083.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Partners, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,640,779.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,640,779.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,640,779.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon Institutional (GP) V, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    108,002.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    108,002.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    108,002.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Farallon F5 (GP), L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    176,083.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    176,083.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    176,083.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.6 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Dapice Joshua J.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Dreyfuss, Philip D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Dunn Hannah E.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Fried, Richard B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Gehani, Varun N.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Giauque, Nicolas
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Husen, Avner A.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Kim, David T.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Linn, Michael G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Luo Patrick (Cheng)
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CHINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Patel, Rajiv A.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Roberts, Jr., Thomas G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Saito Edric C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Seybold, William
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Short Daniel S.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Spokes, Andrew J. M.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Warren, John R.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    29251M106


    1Names of Reporting Persons

    Wehrly, Mark C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,816,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,816,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENANTA PHARMACEUTICALS INC
    (b)Address of issuer's principal executive offices:

    4 Kingsbury Avenue, Watertown, Massachusetts, 02472
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 7 to Schedule 13G (this "Amendment") is filed by the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons". (i) Farallon Capital Partners, L.P., a California limited partnership ("FCP"), with respect to the Shares held by it; (ii) Farallon Capital Institutional Partners, L.P., a California limited partnership ("FCIP"), with respect to the Shares held by it; (iii) Farallon Capital Institutional Partners II, L.P., a California limited partnership ("FCIP II"), with respect to the Shares held by it; (iv) Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership ("FCIP III"), with respect to the Shares held by it; (v) Four Crossings Institutional Partners V, L.P., a Delaware limited partnership ("FCIP V"), with respect to the Shares held by it; (vi) Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership ("FCOI II"), with respect to the Shares held by it; (vii) Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership ("F5MI"), with respect to the Shares held by it; and (viii) Farallon Capital (AM) Investors, L.P., a Delaware limited partnership ("FCAMI"), with respect to the Shares held by it. FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, F5MI and FCAMI are together referred to herein as the "Farallon Funds." (ix) Farallon Partners, L.L.C., a Delaware limited liability company (the "Farallon General Partner"), which is (i) the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and (ii) the sole member of the FCIP V General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI. (x) Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the "FCIP V General Partner"), which is the general partner of FCIP V, with respect to the Shares held by FCIP V. (xi) Farallon F5 (GP), L.L.C., a Delaware limited liability company (the "F5MI General Partner"), which is the general partner of F5MI, with respect to the Shares held by F5MI. (xii) The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, with respect to the Shares held by the Farallon Funds: Joshua J. Dapice ("Dapice"); Philip D. Dreyfuss ("Dreyfuss"); Hannah E. Dunn ("Dunn"); Varun N. Gehani ("Gehani"); Nicolas Giauque ("Giauque"); Avner A. Husen ("Husen"); David T. Kim ("Kim"); Michael G. Linn ("Linn"); Patrick (Cheng) Luo ("Luo"); Thomas G. Roberts, Jr. ("Roberts"); Edric C. Saito ("Saito"); Daniel S. Short ("Short"); Andrew J. M. Spokes ("Spokes"); John R. Warren ("Warren"); and Mark C. Wehrly ("Wehrly"). Dapice, Dreyfuss, Dunn, Gehani, Giauque, Husen, Kim, Linn, Luo, Roberts, Saito, Short, Spokes, Warren and Wehrly are together referred to herein as the "Farallon Individual Reporting Persons." This Amendment reports that effective January 1, 2026, Husen became a member of the Farallon General Partner, a manager of the FCIP V General Partner and a manager of the F5MI General Partner. Accordingly, as of that date, Husen may be deemed a beneficial owner of the Shares held by the Farallon Funds. This Amendment also reports that effective December 31, 2025, each of Richard B. Fried ("Fried"), Rajiv A. Patel ("Patel") and William Seybold ("Seybold") ceased to be a member of the Farallon General Partner, a manager of the FCIP V General Partner and a manager of the F5MI General Partner. Accordingly, as of that date, each of Fried, Patel and Seybold may no longer be deemed a beneficial owner of the Shares held by the Farallon Funds.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.
    (c)Citizenship:

    The citizenship of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner and the F5MI General Partner is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque, Luo and Spokes, is a citizen of the United States. Giauque is a citizen of France. Luo is a citizen of China. Spokes is a citizen of the United Kingdom.
    (d)Title of class of securities:

    Common Stock, par value $0.01 per share (the "Shares")
    (e)CUSIP No.:

    29251M106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person. The Shares reported hereby for the Farallon Funds are held directly by the Farallon Funds. The Farallon General Partner, as the general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner, may be deemed to be a beneficial owner of all such Shares held by the Farallon Funds other than F5MI. The FCIP V General Partner, as the general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares held by FCIP V. The F5MI General Partner, as the general partner of F5MI, may be deemed to be a beneficial owner of all such Shares held by F5MI. Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of all such Shares held by the Farallon Funds. Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.
    (b)Percent of class:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    The Reporting Persons are filing this Schedule 13G pursuant to Section 240.13d-1(c). The Reporting Persons neither disclaim nor affirm the existence of a group among them. Each Reporting Person is a beneficial owner only of the securities reported by it on its cover page.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Farallon Capital Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/05/2026
     
    Farallon Capital Institutional Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/05/2026
     
    Farallon Capital Institutional Partners II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/05/2026
     
    Farallon Capital Institutional Partners III, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/05/2026
     
    Four Crossings Institutional Partners V, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:02/05/2026
     
    Farallon Capital Offshore Investors II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/05/2026
     
    Farallon Capital (AM) Investors, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/05/2026
     
    Farallon Capital F5 Master I, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:02/05/2026
     
    Farallon Partners, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member
    Date:02/05/2026
     
    Farallon Institutional (GP) V, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:02/05/2026
     
    Farallon F5 (GP), L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:02/05/2026
     
    Dapice Joshua J.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Dreyfuss, Philip D.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Dunn Hannah E.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn
    Date:02/05/2026
     
    Fried, Richard B
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Gehani, Varun N.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Giauque, Nicolas
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Husen, Avner A.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Kim, David T.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Linn, Michael G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Luo Patrick (Cheng)
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Patel, Rajiv A.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Roberts, Jr., Thomas G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Saito Edric C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Seybold, William
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Short Daniel S.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Spokes, Andrew J. M.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Warren, John R.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
     
    Wehrly, Mark C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/05/2026
    Exhibit Information

    Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

    Get the next $ENTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTA

    DatePrice TargetRatingAnalyst
    11/14/2025Overweight
    Analyst
    10/1/2025$20.00Hold → Buy
    Jefferies
    7/28/2025$20.00Buy
    H.C. Wainwright
    8/9/2023$14.00Neutral → Underweight
    JP Morgan
    8/8/2023$49.00 → $18.00Buy → Hold
    Jefferies
    12/9/2022$56.00Buy
    H.C. Wainwright
    7/6/2022$62.00In-line → Outperform
    Evercore ISI
    6/1/2022$39.00Underperform → In-line
    Evercore ISI
    More analyst ratings

    $ENTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Enanta Pharmaceuticals

    Analyst initiated coverage of Enanta Pharmaceuticals with a rating of Overweight

    11/14/25 11:26:32 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals upgraded by Jefferies with a new price target

    Jefferies upgraded Enanta Pharmaceuticals from Hold to Buy and set a new price target of $20.00

    10/1/25 10:56:50 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Enanta Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    7/28/25 8:57:53 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Capps Kathleen S. sold $4,596 worth of shares (323 units at $14.23), decreasing direct ownership by 4% to 8,377 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    12/5/25 6:53:20 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Trout Harry R. Iii sold $7,713 worth of shares (542 units at $14.23), decreasing direct ownership by 3% to 16,348 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    12/5/25 6:47:53 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rottinghaus Scott T. sold $11,356 worth of shares (798 units at $14.23), decreasing direct ownership by 4% to 21,792 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    12/5/25 6:46:32 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.

    SCHEDULE 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    2/5/26 2:48:42 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Enanta Pharmaceuticals Inc.

    DEFA14A - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    1/26/26 4:10:39 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Enanta Pharmaceuticals Inc.

    DEF 14A - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    1/26/26 4:05:32 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

    Continuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) Expanding Immunology Pipeline with New Discovery Program Focused on MRGPRX2 Inhibition Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); On Track to Select a Development Candidate in 2H 2026 Advancing EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate; On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 Progressing EPS-3903, an Oral, Once-Daily STAT6 Inhibi

    1/8/26 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enanta's President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30

    1/5/26 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

    Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models Announces EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate with Plans to File an Investigational New Drug Application in Q1 2026 Reported Positive Topline Data for RSVHR, a Phase 2b Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV) Strong Financial Position Ending Fiscal 2025 with $188.9 Million in Cash, Cash Equivalents and Marketable Securities; Further Strengthened by Gross Proceeds of $74.8 Million

    11/17/25 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Luly Jay R. bought $256,050 worth of shares (45,000 units at $5.69), increasing direct ownership by 6% to 846,638 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    2/12/25 8:09:35 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Leadership Updates

    Live Leadership Updates

    View All

    Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

    4/30/24 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

    8/8/22 4:00:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

    1/26/21 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    11/14/24 4:03:02 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    10/17/24 4:31:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    2/14/24 2:26:49 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Financials

    Live finance-specific insights

    View All

    Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 Statistically Significant Improvement in Patient Global Impression of Severity Score Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%) 4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo Management to Host Conference Call and Webcast Today at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases,

    9/29/25 6:30:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast Information The live webcast can be accessed at "Events & Presentations" in the investors section of Enanta's website. To participate by phone

    9/26/25 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

    On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September On Track to Select a STAT6 Development Candidate in 2H 2025 Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor Candidate, in Development for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell Driven Diseases Operations Supported by Cash and Marketable Securities Totaling $204.1 Million at June 30, 2025, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and i

    8/11/25 4:02:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care